Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a Phase 3 randomized trial comparing tebe vs. investigator's choice (IC) in first line metastatic uveal melanomaJessica C. Hassel,Piotr Rutkowski,Jean-Francois Baurain,Marcus O. Butler,Max Schlaak,Ryan J. Sullivan,Sebastian Ochsenreither,Reinhard Dummer,John M. Kirkwood,Anthony M. Joshua,Joseph J. Sacco,Alexander N. Shoushtari,Marlana Orloff,Richard D. Carvajal,Omid Hamid,Shaad E. Abdullah,Chris Holland,Howard Goodall,Paul Nathan,Sophie Piperno-NeumannJOURNAL OF CLINICAL ONCOLOGY(2022)引用 8|浏览0暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要